Stock Research: Sun Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Sun Pharmaceuticals

NSEI:SUNPHARMA INE044A01036
35
  • Value
    70
  • Growth
    31
  • Safety
    Safety
    39
  • Combined
    32
  • Sentiment
    48
  • 360° View
    360° View
    35
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Sun Pharmaceutical Industries Limited is a specialty generic pharmaceutical company. It operates in the specialty, generics, and consumer healthcare product industries. The company operates globally, with a focus on dermatology, ophthalmology, and onco-dermatology products. In the last fiscal year, the company had a market cap of $47,477 million, profits of $4,726 million, and revenue of $6,153 million with 43,000 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 35 (better than 35% compared with alternatives), overall professional sentiment and financial characteristics for the stock Sun Pharmaceuticals are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Sun Pharmaceuticals. The only rank that is above average is the consolidated Safety Rank at 70, which means that the company has a financing structure that is safer than those of 70% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 39, which means that the share price of Sun Pharmaceuticals is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 31, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 48, which means that professional investors are more pessimistic about the stock than for 52% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
BSE Sensex
Good Governace Growth Markets
CNX Nifty 50
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
39 33 41 53
Growth
31 81 61 53
Safety
Safety
70 61 43 61
Sentiment
48 97 96 58
360° View
360° View
35 89 82 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
79 64 91 74
Opinions Change
8 75 49 52
Pro Holdings
n/a 90 85 16
Market Pulse
55 96 75 65
Sentiment
48 97 96 58
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
39 33 41 53
Growth
31 81 61 53
Safety Safety
70 61 43 61
Combined
32 73 43 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
36 40 46 50
Price vs. Earnings (P/E)
29 19 34 46
Price vs. Book (P/B)
41 37 45 56
Dividend Yield
55 48 43 46
Value
39 33 41 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
53 56 49 37
Profit Growth
30 57 42 16
Capital Growth
17 80 67 70
Stock Returns
63 75 63 75
Growth
31 81 61 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
71 62 50 62
Refinancing
53 40 48 58
Liquidity
70 84 64 61
Safety Safety
70 61 43 61

Similar Stocks

Discover high‑ranked alternatives to Sun Pharmaceuticals and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.